Expedition Medicines develops an AI-powered platform that creates small-molecule drugs for previously inaccessible disease targets.
Expedition Medicines has raised $50.0M in total funding. The most recent round was Series A. The last funding was announced in October 2025.
Expedition Medicines's investors include Flagship Pioneering.
Expedition Medicines is headquartered in Cambridge, United States.
Expedition Medicines develops an AI-powered platform that creates small-molecule drugs for previously inaccessible disease targets.
Expedition Medicines is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Expedition Medicines — Funding & Investors." VCBacked, October 22, 2025, https://www.vcbacked.co/company/expedition-medicines. Accessed August 14, 2026.
VCBacked. (2025). Expedition Medicines — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/expedition-medicines
{{cite web |title=Expedition Medicines — Funding & Investors |url=https://www.vcbacked.co/company/expedition-medicines |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated